Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
394
-
Total 13F shares, excl. options
-
64.4M
-
Shares change
-
+5.41M
-
Total reported value, excl. options
-
$2.54B
-
Value change
-
+$195M
-
Put/Call ratio
-
1.26
-
Number of buys
-
154
-
Number of sells
-
-184
-
Price
-
$39.36
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2024
505 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2024.
CRISPR Therapeutics AG - Common Stock (CRSP) has 394 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.4M shares
of 86M outstanding shares and own 74.95% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.97M shares), Capital International Investors (8.74M shares), T. Rowe Price Investment Management, Inc. (3.81M shares), BlackRock, Inc. (2.76M shares), Nikko Asset Management Americas, Inc. (2.75M shares), Sumitomo Mitsui Trust Group, Inc. (2.75M shares), STATE STREET CORP (2.49M shares), FMR LLC (2.22M shares), UBS Group AG (1.98M shares), and VANGUARD GROUP INC (1.74M shares).
This table shows the top 394 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.